Sign In
Buy PHGE
$0.184
-0.0046 (-2.44%)
At Close: Jul 31, 2026
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
10:56am, Friday, 18'th Apr 2025
BiomX (PHGE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend
BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure
06:30am, Tuesday, 01'st Apr 2025
NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therap
The Company will host a conference call and webcast today at 9:00 AM ET, followed by a Key Opinion Leader (KOL) event on April 3, 2025, at 11:00 AM ET to discuss the results
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
06:30am, Tuesday, 25'th Mar 2025
NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapi
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
12:35pm, Wednesday, 19'th Mar 2025
NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therap
BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript
10:20am, Thursday, 14'th Nov 2024
BiomX Inc. (NYSE:PHGE ) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ET Company Participants Marina Wolfson – Chief Financial Officer Jonathan Solomon – Chief Executive Officer Confe
BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates
06:30am, Thursday, 14'th Nov 2024
BX211 Phase 2 for treatment of Diabetic Foot Osteomyelitis (DFO) patient enrollment completed and on track to report topline results in Q1 2025
BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024
12:20pm, Tuesday, 12'th Nov 2024
NESS ZIONA, Israel, Nov. 12, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapi
BiomX Announces a Mandatory Unit Separation
07:00am, Tuesday, 15'th Oct 2024
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapie
BiomX Stock Gains From Favorable Study Data Presentation on BX004
09:35am, Friday, 20'th Sep 2024
PHGE is set to present data from its Phase 1b/2a study for BX004 at the North American Cystic Fibrosis Conference in Boston on Sept. 27 and Sept.
BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference
08:00am, Wednesday, 18'th Sep 2024
GAITHERSBURG, Md., Sept. 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapi
BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08:00am, Wednesday, 04'th Sep 2024
GAITHERSBURG, Md., Sept. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapi
UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split
10:55am, Friday, 16'th Aug 2024
In a release issued under the same headline yesterday by BiomX (NYSE American: PHGE), the third and fourth paragraphs have been updated to include information regarding adjustment of outstanding units
BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript
12:03pm, Thursday, 15'th Aug 2024
BiomX Inc. (NYSE:PHGE ) Q2 2024 Earnings Call Transcript August 15, 2024 8:00 AM ET Company Participants Marina Wolfson - CFO Jonathan Solomon - CEO Conference Call Participants Yale Jen - Laidlaw & C
BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates
06:30am, Thursday, 15'th Aug 2024
BiomX anticipates reporting important results in 2025 for two clinical assets from the Company's leading pha ge therap y pipeline
